AbbVie completes acquisition of Nimble Therapeutics
MLex Summary: AbbVie has completed its acquisition of Nimble Therapeutics. Nimble's lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis, the company said.See...To view the full article, register now.
Already a subscriber? Click here to view full article